GORE TAG CONFORMABLE Thoracic Stent Graft with ACTIVE CONTROL System

FDA Device Recall #Z-0290-2021 — Class II — September 9, 2020

Recall Summary

Recall Number Z-0290-2021
Classification Class II — Moderate risk
Date Initiated September 9, 2020
Status Ongoing
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm W L Gore & Associates, Inc.
Location Flagstaff, AZ
Product Type Devices
Quantity 13860 units

Product Description

GORE TAG CONFORMABLE Thoracic Stent Graft with ACTIVE CONTROL System

Reason for Recall

Due to secondary deployment fiber being attached to secondary deployment handle, completion of deployment via the deployment line access hatch was not possible

Distribution Pattern

U.S. - Nationwide O.U.S. - Australia, Austria, Belgium, Croatia, Cypress, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Lebanon, Luxembourg, Monaco, Netherlands, Norway, New Zealand, Poland, Portugal, Saudi Arabia, Slovenia, South Africa, Spain, Sweden, Switzerland, United Arab Emirates, and United Kingdom

Lot / Code Information

CATALOG NUMBERS TGM212110X* TGM212115X* TGM212120X* TGM262610X* TGM262615X* TGM262620X* TGM282810X* TGM282815X* TGM282820X* TGM313110X* TGM313115X* TGM313120X* TGM343410X* TGM343415X* TGM343420X* TGM373710X* TGM373715X* TGM373720X* TGM404010X* TGM404015X* TGM404020X* TGM454510X* TGM454515X* TGM454520X* TGM262110X* TGM312610X* TGMR313110X* TGMR313115X* TGMR313120X* TGMR312610X* TGMR373710X* TGMR373715X* TGMR373720X* TGMR404010X* TGMR404015X* TGMR404020X* *X is a placeholder for enumeration code: E=EMEA, Australia, New Zealand; J=Japan All lot numbers

Other Recalls from W L Gore & Associates, Inc.

Recall # Classification Product Date
Z-0036-2026 Class II GORE ACUSEAL Vascular Graft, REF: ECH050020J, E... Aug 26, 2025
Z-2946-2024 Class II Heparin, Gore Viabahn VBX, Balloon Expandable E... Jul 1, 2024
Z-2945-2024 Class II Heparin, Gore Viabahn VBX, Balloon Expandable E... Jul 1, 2024
Z-1048-2023 Class II GORE CARDIOFORM Septal Occluder, REF: GSX0030A Dec 14, 2022
Z-0136-2023 Class II GORE CARDIOFORM ASD Occluder. cardiovascular im... Sep 21, 2022

Frequently Asked Questions

Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.

Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.

Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.

What Should You Do?

Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.